BIOMAT Database Logo BIOMAT Database Logo

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. 2011

O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
Pulmonary Division, Internal Medicine, University Hospital, Mainz, Germany. kornmann@ikf-pneumologie.de

Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β(2)-agonist bronchodilator recently approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). The aim of the present study was to investigate the efficacy and safety of indacaterol compared with placebo and the twice-daily β(2)-agonist, salmeterol, as an active control. Patients with moderate-to-severe COPD were randomised to 6 months double-blind treatment with indacaterol (150 μg once daily), salmeterol (50 μg twice daily) or placebo. The primary efficacy end-point was trough (24 h post-dose) forced expiratory volume in 1 s (FEV(1)) after 12 weeks. 1,002 patients were randomised and 838 (84%) completed the study. Indacaterol increased trough FEV(1) at week 12 by 170 mL over placebo (p<0.001) and by 60 mL over salmeterol (p<0.001). Both active treatments improved health status (St George's Respiratory Questionnaire) and dyspnoea (transition dyspnoea index) compared with placebo, with differences between them favouring indacaterol. Safety profiles were similar across the treatment groups, and both indacaterol and salmeterol were well tolerated. Once-daily treatment with 150 μg indacaterol had a significant and clinically relevant bronchodilator effect over 24 h post-dose and improved health status and dyspnoea to a greater extent than twice-daily 50 μg salmeterol. Indacaterol should prove a useful additional treatment for patients with COPD.

UI MeSH Term Description Entries
D007189 Indans Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES. Indanones
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004417 Dyspnea Difficult or labored breathing. Orthopnea,Platypnea,Recumbent Dyspnea,Rest Dyspnea,Trepopnea,Breathlessness,Shortness of Breath,Breath Shortness,Dyspnea, Recumbent,Dyspnea, Rest,Dyspneas, Rest
D005260 Female Females
D006304 Health Status The level of health of the individual, group, or population as subjectively assessed by the individual or by more objective measures. General Health,General Health Level,General Health Status,Level of Health,Overall Health,Overall Health Status,General Health Levels,Health Level,Health Level, General,Health Levels,Health Status, General,Health Status, Overall,Health, General,Health, Overall,Level, General Health,Levels, General Health,Status, General Health,Status, Health,Status, Overall Health

Related Publications

O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.
May 2011, Respiratory medicine,
O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.
January 2015, The Cochrane database of systematic reviews,
O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
October 2020, The Lancet. Respiratory medicine,
O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
June 2010, Thorax,
O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
June 2016, The New England journal of medicine,
O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
October 2020, The Lancet. Respiratory medicine,
O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma: post hoc pooled analysis from PALLADIUM and IRIDIUM studies.
August 2022, The Journal of asthma : official journal of the Association for the Care of Asthma,
O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
October 2011, The European respiratory journal,
O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
[COPD--comparison between once- and twice daily administration of formoterol]].
December 2007, Pneumologie (Stuttgart, Germany),
O Kornmann, and R Dahl, and S Centanni, and A Dogra, and R Owen, and C Lassen, and B Kramer, and
Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
February 2015, Pulmonary pharmacology & therapeutics,
Copied contents to your clipboard!